

Association of Presalvage Radiotherapy PSA Levels After Long-term Antiandrogen Therapy in Men With Prostate

JAMA Oncology

6, 735

DOI: [10.1001/jamaoncol.2020.0109](https://doi.org/10.1001/jamaoncol.2020.0109)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Outcome After ⁶⁸ Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. <i>Cancers</i> , 2020, 12, 3395.	1.7	7
2	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). <i>European Urology</i> , 2021, 80, 280-292.	0.9	140
3	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	5.1	79
4	Prednisone reduction for metastatic castration-resistant prostate cancer with recurrent pulmonary tuberculosis. <i>Medicine (United States)</i> , 2021, 100, e25584.	0.4	1
5	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 544.	3.4	82
6	Radiotherapy in nodal oligorecurrent prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 575-580.	1.0	11
7	Outcomes and Prediction Models for Exclusive Prostate Bed Salvage Radiotherapy among Patients with Biochemical Recurrence after Radical Prostatectomy. <i>Cancers</i> , 2021, 13, 2672.	1.7	4
8	Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. <i>European Urology Oncology</i> , 2022, 5, 304-313.	2.6	12
9	A Comprehensive Assessment of ⁶⁸ Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 567-572.	2.8	20
10	Salvage therapy for prostate cancer after radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 643-668.	1.9	26
11	The prognostic value, sensitivity, and specificity of multiparametric magnetic resonance imaging before salvage radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2021, 161, 9-15.	0.3	6
13	Exercise: A Treatment That Should Be Prescribed With Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.4	0
17	Using hormone therapy with salvage radiotherapy according to presalvage PSA levels. <i>Nature Reviews Urology</i> , 2020, 17, 489-490.	1.9	0
18	Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 17588359211051870.	1.4	1
19	Post-Operative Radiotherapy in Prostate Cancer: Is It Time for a Belt and Braces Approach?. <i>Frontiers in Oncology</i> , 2021, 11, 781040.	1.3	3
20	Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110518.	1.4	3
21	Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 305-315.	0.4	5
22	Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 787347.	1.3	7

#	ARTICLE	IF	CITATIONS
23	Management of patients with a persistently elevated PSA after radical prostatectomy: a narrative review. <i>World Journal of Urology</i> , 2022, , 1.	1.2	2
24	Narrative Review of the Post-Operative Management of Prostate Cancer Patients: Is It Really the End of Adjuvant Radiotherapy?. <i>Cancers</i> , 2022, 14, 719.	1.7	1
25	Moderate hypofractionation for salvage radiotherapy (HYPO-SRT) in patients with biochemical recurrence after prostatectomy: A cohort study with meta-analysis. <i>Radiotherapy and Oncology</i> , 2022, 171, 7-13.	0.3	4
26	Adjuvant or Salvage Radiation Therapy for Prostate Cancer after Prostatectomy: Current Status, Controversies and Perspectives. <i>Cancers</i> , 2022, 14, 1688.	1.7	6
27	Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 780507.	1.3	3
28	Postoperative radiotherapy in prostate cancer: When and how? An update review. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, , .	0.6	1
29	Best Approaches and Updates for Prostate Cancer Biochemical Recurrence. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 352-359.	1.8	10
30	The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1886-1901.	6.3	89
31	Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 316-319.	0.4	0
32	Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data. <i>Annals of Surgical Oncology</i> , 2022, 29, 7206-7215.	0.7	3
33	Genomic biomarkers to guide precision radiotherapy in prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	3
34	RADICALS-HD: Reflections before the Results are Known. <i>Clinical Oncology</i> , 2022, 34, 593-597.	0.6	2
35	The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. <i>Scandinavian Journal of Urology</i> , 2022, 56, 278-284.	0.6	10
36	PROshot: Prone Positioning, Radiation First in Total Neoadjuvant Therapy, Palliative Craniospinal Irradiation, Long-Term Androgen Deprivation Therapy, and Combining Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Coverage With Salvage Prostate Radiation. <i>Practical Radiation Oncology</i> , 2022, 12, 387-391.	1.1	0
37	How can we best manage biochemical failure after radical prostatectomy?. <i>Investigative and Clinical Urology</i> , 2022, 63, 592.	1.0	1
38	The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy. <i>Prostate</i> , 0, , .	1.2	1
39	Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 1307-1317.	0.8	6
40	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease. <i>Progres En Urologie</i> , 2022, 32, 1275-1372.	0.3	15

#	ARTICLE	IF	CITATIONS
41	Radiation therapy post radical prostatectomy: who, when and why?. Current Opinion in Supportive and Palliative Care, 0, Publish Ahead of Print, .	0.5	0
42	Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology, 2023, 83, 267-293.	0.9	39
43	Re: The Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy (NRG Oncology/RTOG 0534 SPPORT): An International, Multicentre, Randomised Phase 3 Trial. European Urology, 2023, , .	0.9	0
44	Efficacy and safety of salvage radiotherapy combined with endocrine therapy in patients with biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Oncology, 0, 12, .	1.3	0
45	Immunological analysis of Interleukin-10 (IL-10), tumor necrosis factor- α (TNF- α), and Prostate-specific antigen (PSA) in benign and malignant prostate cancer. Human Antibodies, 2023, , 1-9.	0.6	2
46	ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer. Radiotherapy and Oncology, 2023, 183, 109544.	0.3	6
47	Multimodality Therapies for Localized Prostate Cancer. Current Oncology Reports, 2023, 25, 221-229.	1.8	1
51	Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer and Prostatic Diseases, 0, , .	2.0	2
56	Prostate cancer and elective nodal radiation therapy for cN0 and pN0 – a never ending story?. Strahlentherapie Und Onkologie, 2024, 200, 181-187.	1.0	0